Related Content
Abbott Vascular's XIENCE V Everolimus-Eluting Coronary is indicated for improving coronary luminal diameter in patients ...
January 28, 2009 - Data published this week in the online journal Circulation from the SPIRIT III U.S. pivotal trial ...
December 18, 2008 - Abbott this week said it started the SPIRIT Small Vessel, a clinical trial evaluating a 2.25mm size ...
December 15, 2008 - The FDA has approved Abbott's TRILIPIX (fenofibric acid) delayed-release capsules, the first and ...
October 30, 2008 - Abbott this week received a 2008 Chicago Innovation Award for its XIENCE V Everolimus Eluting ...
October 20, 2008 – At TCT last week Abbott announced two-year data from 30 patients in its ABSORB clinical trial ...
October 13, 2008 — Data from an independent meta-analysis of Abbott Vascular’s SPIRIT II and SPIRIT III randomized ...
August 20, 2008 - Diagnostic testing conducted at or near the site of the patient, known as patient-side point-of-care ...
August 15, 2008 - Abbott and AstraZeneca said this week they entered into an agreement for Abbott to promote AstraZeneca ...
The StarClose SE Vascular Closure System is a next-generation vessel closure device engineered to enable fast and secure ...